Poster
Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT ‘basket’ trial
Author
James J. Harding
Condition
biliary tract cancers
Drug target
HER2
Drug moa
tyrosine kinase inhibitor
Source url
s3://convoke-optic-posters/2024-05-10/060422_Puma_at_ASCO_-_SUMMIT_biliary_poster_-_FINAL.pdf
11 organizations
1 product
Product
NeratinibOrganization
Memorial Sloan Kettering Cancer CenterOrganization
MD Anderson Cancer CenterOrganization
Dana Farber Cancer Institute, Boston, MAOrganization
USC Norris Cancer Hospital, Los Angeles, CAOrganization
Vall d’Hebron University Hospital/VHIOOrganization
START Madrid-FJDOrganization
Mayo ClinicOrganization
Stanford Cancer InstituteOrganization
Puma Biotechnology Inc, Los Angeles, CA